TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02709538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSP 301 NS
Description: FDC of olopatadine HCl and mometasone furoate: 2 spray in each nostril twice daily for 52 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSP 301 Placebo NS pH 3.7
Description: 2 spray in each nostril twice daily for 52 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSP 301 Placebo NS pH 7.0
Description: 2 spray in each nostril twice daily for 52 weeks
Study: NCT02343549

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoTTF100A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Study: NCT02284841

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hilotherm cooling face mask
Description: Hilotherapy - use of an external cooling device; a facial mask through which water circulates at a controlled temperature, allowing continuous cooling of the face, and is thought to reduce post-operative swelling and pain.
Study: NCT02160041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGJ398
Description: BGJ398 was dosed on a flat scale of 125 mg (e.g., 1 x 100 mg and 1 x 25 mg capsules) once daily for the first 21 days of the 28-day cycle (3 weeks on, 1 week off in a cycle). A complete treatment cycle is defined as 28 days.
Study: NCT01717599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac
Description: Diclofenac 90mg, 2ml/A, IM(intramuscular) injection immediately after procedure of ERCP

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: normal saline 2ml/A, IM(intramuscular) injection immediately after procedure of ERCP
Study: NCT04379128

Intervention type: OTHER
Intervention: Attentional tasks
Description: a neuropsychological assessment of attentional task, executive task and interview is proposed to patients or normal control

Intervention type: OTHER
Intervention: Attentional tasks
Description: a neuropsychological assessment of attentional task, executive task and interview is proposed to patients or normal control
Study: NCT01906996

Intervention type: PROCEDURE
Intervention: proximal row carpectomy
Description: excision of the scaphoid, lunate and triquetrum
Study: NCT03849339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D635
Description: Reference drug
Study: NCT02833246

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS/MMS text messaging
Description: text messaging reminders on oral chemotherapy medication adherence

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Study: NCT03657615

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hearing aid fitting
Description: All patients were fitted bilaterally with hearing aids for hearing loss compensation. . Apart from different HAs used, device selection followed strict criteria to fit hearing loss demands, patient profile, resources and algorithms recommended for tinnitus patients.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hearing aid fitting
Description: All patients were fitted bilaterally with hearing aids for hearing loss compensation. . Apart from different HAs used, device selection followed strict criteria to fit hearing loss demands, patient profile, resources and algorithms recommended for tinnitus patients.
Study: NCT02843620

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: b-2Cool
Description: b-2Cool® is native type II collagen extracted from chicken sternums

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Excipients only
Study: NCT02793037

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zirconia resin bonded bridge
Study: NCT04588324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR2150
Description: Patients will receive escalating doses of SHR-2150 (starting dose 2 mg) in 3-week treatment cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Cancer Agent
Description: The previously resistant first-line cytotoxic regimens, anti-PD-1 antibody and/or anti-CD47 antibody will be administered intravenously Q3W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Cancer Agent
Description: The previously resistant first-line cytotoxic regimens, anti-PD-1 antibody and/or anti-CD47 antibody will be administered intravenously Q3W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR2150
Description: Patients will receive SHR-2150 at RP2D in 3-week treatment cycles.
Study: NCT02486315

Intervention type: DEVICE
Intervention: AXXESS stent
Description: Axxess stent is a conically-shaped, self-expanding nitinol stent, with a 0.006-inch strut thickness, specifically designed to preserve and to match the anatomy of the bifurcation at the carina level. The stent is coated with Biolimus A9™, a highly lipophilic, semi-synthetic sirolimus analogue, immersed in the biodegradable polylactic acid (PLA) applied primarily to the abluminal surface. PLA completely dissolves after 6 to 9 months.The stent has 3 radiopaque markers at the distal end and one at the proximal end to aid in the visibility and placement. The AxxessTM stent is 7 Fr guiding catheter or Sheathless Guiding Catheter compatible. During the study period, the AxxessTM stent was available in 3 different diameters (3.0, 3.5 and 4.0 mm) and lengths (9, 10 and 14 mm)
Study: NCT01629147

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Biogaia
Description: 5 drops containing Lactobacillus reuteri Protectis

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 drops
Study: NCT04838873

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open radical cystectomy
Description: Standard open radical cystectomy and urinary diversion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted radical cystectomy
Description: Laparoscopic-assisted radical cystectomy and extracorporeal urinary diversion
Study: NCT01583621

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: The participants will be randomized into one of the four groups. Group 0 will be placebo group, group 1 will receive monthly supervised dose of 18,000 IU (equivalent to 600 IU/day), group 2 will receive monthly supervised dose of 60,000 IU(equivalent to 2000 IU/day), and group 3 will receive 120,000 IU (equivalent to 4000 IU/day) vitamin D3 supplementation for 4 months (16 weeks).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: The participants will be randomized into one of the four groups. Group 0 will be placebo group, group 1 will receive monthly supervised dose of 18,000 IU (equivalent to 600 IU/day), group 2 will receive monthly supervised dose of 60,000 IU(equivalent to 2000 IU/day), and group 3 will receive 120,000 IU (equivalent to 4000 IU/day) vitamin D3 supplementation for 4 months (16 weeks).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: The participants will be randomized into one of the four groups. Group 0 will be placebo group, group 1 will receive monthly supervised dose of 18,000 IU (equivalent to 600 IU/day), group 2 will receive monthly supervised dose of 60,000 IU(equivalent to 2000 IU/day), and group 3 will receive 120,000 IU (equivalent to 4000 IU/day) vitamin D3 supplementation for 4 months (16 weeks).
Study: NCT01149265

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online support group
Description: Expressive writing involves people writing about their thoughts and feelings, often upsetting ones, for a short period of time.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Expressive writing
Description: Online support groups are internet forums where like-minded people give and receive both informational and emotional support.
Study: NCT00150592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD503 (Guanfacine HCl)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01871961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (Metoject® prefilled pen)
Study: NCT02262494

Intervention type: PROCEDURE
Group type: OTHER
Intervention: portable venous compression ultrasonography
Description: venous compression ultrasonography performed using an ultra-portable ultrasound device (by emergency physician)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: venous compress ultrasonography
Description: venous compression ultrasonography performed using a classic ultrasound device (by exploratory specialist)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Doppler ultrasound of the lower limbs
Description: Doppler ultrasound of the lower limbs (gold standard; by exploratory specialist)
Study: NCT04365465

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NSS-2 Bridge
Description: The NSS-2 BRIDGE (Appendix 1) is a battery operated and disposable percutaneous auricular nerve field stimulator (Innovative Health Solutions, Versailles, IN, USA), that was recently cleared by the FDA and assigned a Class II Risk Designation; a class which includes surgical drapes, pumps and power wheelchairs.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Inactive NSS-2 Bridge
Description: This is a sham device which is identical to the active NSS-2 Bridge, but will not provide percutaneous auricular nerve field stimulation when applied.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active control
Description: Active control will include standard of care pain management during the postoperative period. Participants in this intervention arm will not receive or wear a device.
Study: NCT01138956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: N-acetylcysteine (NAC), effervescent tablets of 600mg, tid, po, 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentavalent antimonial
Description: Pentavalent antimonial, 20mg/kg/day, 28 days, IV
Study: NCT04710095

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Alcohol Intervention
Description: Brief alcohol intervention uses a motivational interviewing approach and covers the following components: giving information about the possible health risks associated with alcohol use, placing the responsibility for change on the individual, discussing the reasons for drinking and downsides of drinking, and setting a goal and change plan if the participant is receptive.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control Condition
Description: The attention-matched control condition consisting of a 30-min video about astronomy.
Study: NCT00006388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen citrate

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT04272931

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Portal and Hepatic Vein Embolization
Description: Procedure/Surgery: Combined portal vein embolization and hepatic vein embolization (PVE/HVE) • All techniques of PVE allowed (ipsi-lateral, contra-lateral, trans-splenic, all embolization agents except for ethanol alone) • All modifications of HVE allowed (venous occlusion umbrellas; trans-jugular, trans-hepatic, no use of vein glue to avoid lung embolization; staged approach allowed, but first PVE, then HVE and within 48 hours)
Study: NCT01317680

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Omnispec model ED1000
Description: Device: Extracorporeal Shockwave Therapy Generator (Omnispec model ED1000) Gel is spread around the penis and on the Shock Wave applicator and Treatment (12 sessions in total) of 300 shocks per site, on 5 penile anatomical sites.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham control
Description: We use the same probe that induces the same sensation on the penis and the same noise yet no energy
Study: NCT04381442

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low Level Laser Therapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Low Level Laser Therapy
Study: NCT02381431

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FLIR ONE
Study: NCT00328627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin tablets.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alogliptin placebo
Description: Alogliptin placebo-matching tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alogliptin placebo
Description: Alogliptin placebo-matching tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alogliptin placebo
Description: Alogliptin placebo-matching tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone placebo
Description: Pioglitazone placebo-matching tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone placebo
Description: Pioglitazone placebo-matching tablets.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pioglitazone placebo
Description: Pioglitazone placebo-matching tablets.
Study: NCT04437212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Patients received toripalimab 240mg every 3 weeks 1-7 days after neoadjuvant chemoradiotherapy for 2 cycles before operation and 28-42 days after operation for 4 cycles.
Study: NCT01636466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus will initially be dosed at 0.75 mg tablet taken orally twice a day. The dose will be adjusted to maintain serum trough concentrations of 5-8 ng/ml.
Study: NCT00916240

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multisystemic Therapy
Description: Treatment will consist of a home- and community-based intensive intervention. Psychological treatment sessions will be provided in participants' homes, at a time designated by the participant and will last about 1 hour.
Study: NCT01906996

Intervention type: PROCEDURE
Intervention: four corner fusion
Description: excision of the scaphoid and stiffening of the lunate, capitate and triquetrum by a plate
Study: NCT04375540

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Upper first premolars extractions
Description: Fixed orthodontic treatment with upper first premolars extraction and space closure using 0.019X0.025 SS AW and elastic chain.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Upper second premolars extraction
Description: Fixed orthodontic treatment with upper second premolars extraction and space closure using 0.019X0.025 SS AW and elastic chain.
Study: NCT04316832

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness based cognitive training
Description: The mindfulness based cognitive training will include three short mindfulness exercises: a) a breathing exercise, b) a body scan exercise, and c) a mindfulness attention exercise.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control exercise
Description: Participants will listen to the first chapter of the audiobook The Hobbit, JRR Tolkien.
Study: NCT04243382

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous umbilical cord blood
Description: Single infusion of autologous umbilical cord blood cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT00492713

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dark chocolate
Description: dark chocolate
Study: NCT00916240

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home-based, Non-Directive Family Support
Description: Treatment will consist of Rogerian, client-centered, non-directive counseling. Participants will receive weekly home-based, supportive family counseling, with sessions lasting about 45 minutes.
Study: NCT00492713

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Milk chocolate 1
Description: Milk chocolate 1
Study: NCT01272466

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: peptides derived from antiapoptotic proteins
Description: 8 Vaccinations on day 2 and 9 in every bortezomib treatment series
Study: NCT01765673

Intervention type: DEVICE
Intervention: Vibrotactile stimulation
Description: Comparison of the effects of different vibratory characteristics on the frequency of swallowing, time of initiation of swallowing with stimulation and urge to swallow. Will compare frequency of vibration, mode of vibration, pressure of device against neck, and duration of vibration. Each session will last no more than 1 hour with short breaks. Each participant can volunteer for up to three nonconsecutive sessions.
Study: NCT02304198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Udenafil
Description: Udenafil 50mg tablet
Study: NCT01975922

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Milieu Teaching
Description: Enhanced Milieu Teaching (EMT) is a conversation-based model of early language intervention that uses child interest and initiations as opportunities to model and prompt language use in everyday contexts.
Study: NCT00606242

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone
Description: Inhaled Fluticasone, either 100 or 1000 mcg per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone
Description: Inhaled Fluticasone, either 100 or 1000 mcg per day
Study: NCT03133845

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Light sedation with propofol
Description: Patients having lumbar spinal surgery and receiving spinal anesthesia will receive propofol for light sedation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Induction with propofol
Description: Patients having lumbar spinal surgery and receiving general anesthesia will receive propofol and their induction agent.
Study: NCT00492713

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Milk chocolate 2
Description: Milk chocolate 2
Study: NCT03133845

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maintenance anesthetic using a volatile anesthetic
Description: Patients having lumbar spinal surgery and receiving general anesthesia will receive a volatile anesthetic for their maintenance anesthesia.
Study: NCT02128685

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dydrogesterone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03133845

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Muscle relaxant during maintenance anesthesia
Description: Patients having lumbar spinal surgery and receiving general anesthesia with receive a muscle relaxant for muscle paralysis.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pain control with fentanyl
Description: Patients having lumbar spinal surgery and receiving general anesthesia will receive fentanyl for their pain during surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bispectral Index (BIS) monitoring for depth of anesthesia
Description: All patients will be monitored with Bispectral Index (BIS) to monitor the patient's depth of anesthesia.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bispectral Index (BIS) monitoring for depth of anesthesia
Description: All patients will be monitored with Bispectral Index (BIS) to monitor the patient's depth of anesthesia.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal Anesthesia
Description: Patients receiving spinal anesthesia will receive bupivacaine into the subarachnoid space.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Midazolam administered during spinal anesthesia
Description: Midazolam may be administered during spinal needle insertion for patients receiving spinal anesthesia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cerebrospinal fluid collection
Description: 8 ml of cerebrospinal fluid may be collected prior to the administration of intrathecal administration of morphine for pain control.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid collection
Description: 8 ml of cerebrospinal fluid may be collected prior to the administration of intrathecal administration of morphine for pain control.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Administration of intrathecal morphine
Description: Patient may receive intrathecal morphine for post-operative pain control.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Administration of intrathecal morphine
Description: Patient may receive intrathecal morphine for post-operative pain control.
Study: NCT03536351

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interdisciplinary process drama
Description: Process drama program (3 days/week, 12 weeks, 1-1.5 hours per session) of movement-based activities combining music and drama. Activities that target understanding of emotions, intentions, and appropriate social interactions have been planned by a team of drama teachers, occupational therapists, and speech-language pathologists.
Study: NCT00141765

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Myeloablative Chemotherapy
Description: High dose chemotherapy (carboplatin and thiotepa) transplant rescue

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Rescue
Description: autologous stem cell transplantation